![]() “From the release of our pivotal data for axi-cel, to our potential approval by the FDA, this is a year of milestones. KITE shares were trading at $179.20 apiece in pre-market activity, up 29%. Our similar cultures and histories of driving rapid innovation in order to bring more effective and safer products to as many patients as possible make this an excellent strategic fit.” We are greatly impressed with the Kite team and what they have accomplished, and share their belief that cell therapy will be the cornerstone of treating cancer. ![]() “The field of cell therapy has advanced very quickly, to the point where the science and technology have opened a clear path toward a potential cure for patients. “The acquisition of Kite establishes Gilead as a leader in cellular therapy and provides a foundation from which to drive continued innovation for people with advanced cancers,” Gilead president & CEO John Milligan said in prepared remarks. The regulatory watchdog is scheduled to make a decision about axi-cel by Nov. The treatment is under priority by the FDA. The company’s most advanced candidate, a chimeric antigen receptor, could be the first to market as a therapy for refractory aggressive non-Hodgkin lymphoma. Kite’s pipeline consists of cell therapies that use a patient’s own immune cells to fight cancer. Gilead said it plans to pay $180 in cash for each Kite Pharma share – a 29% premium to the company’s price per share at close last week. The deal, which was unanimously approved by both companies’ boards, is slated to close in the fourth quarter of this year. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.Taking a plunge into the cell therapy arena, Gilead Sciences (NSDQ: GILD) said today that it has inked an $11.9 billion deal to acquire Kite Pharma (NSDQ: KITE). NASDAQ data is at least 15 minutes delayed. NYSE and AMEX data is at least 20 minutes delayed. Visit to get our data and content for your mobile app or website. Visit Performance Disclosure for information about the performance numbers displayed above. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. The monthly returns are then compounded to arrive at the annual return. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. These returns cover a period from Januthrough September 12, 2022. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.51% per year. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. and Morningstar, Inc.Ĭopyright 2022 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606Īt the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Forbes Media, LLC Investor's Business Daily, Inc. Each of the company logos represented herein are trademarks of Microsoft Corporation Dow Jones & Company Nasdaq, Inc. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. NA Value | NA Growth | NA Momentum | NA VGM Zacks Style Scores Education - Learn more about the Zacks Style Scores That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. As you might remember from your school days, an A, is better than a B a B is better than a C a C is better than a D and a D is better than an F.Īs an investor, you want to buy stocks with the highest probability of success. Within each Score, stocks are graded into five groups: A, B, C, D and F. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. The scores are based on the trading styles of Value, Growth, and Momentum. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |